Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. announced that the independent Data Monitoring Committee (DMC) conducted a final safety review of the fully enrolled Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as adjunct therapy for Hypoplastic Left Heart Syndrome (HLHS). The DMC found no new safety concerns, approved continuation to completion, and top-line result…